MX348723B - Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva. - Google Patents

Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.

Info

Publication number
MX348723B
MX348723B MX2013013125A MX2013013125A MX348723B MX 348723 B MX348723 B MX 348723B MX 2013013125 A MX2013013125 A MX 2013013125A MX 2013013125 A MX2013013125 A MX 2013013125A MX 348723 B MX348723 B MX 348723B
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
effective amount
therapeutically effective
patient
Prior art date
Application number
MX2013013125A
Other languages
English (en)
Other versions
MX2013013125A (es
Inventor
Mehdi Paborji
Roger S Flugel
Keneeth L Duchin
Wendy Jade Limayo Hernandez
Original Assignee
Theravida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravida Inc filed Critical Theravida Inc
Publication of MX2013013125A publication Critical patent/MX2013013125A/es
Publication of MX348723B publication Critical patent/MX348723B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Laminated Bodies (AREA)

Abstract

Se divulgan composiciones farmacéuticas que comprenden una cantidad terapéuticamente eficaz de solifenacina de liberación prolongada, o su sal farmacéuticamente aceptable, y una cantidad terapéuticamente eficaz de pilocarpina, o su sal farmacéuticamente aceptable. También se divulgan métodos para tratar a un paciente que sufre de vejiga hiperactiva, el método comprende la identificación de un paciente en necesidad del mismo, y la administración al paciente de una cantidad terapéuticamente eficaz de solifenacina de liberación prolongada o su sal farmacéuticamente aceptable, y una cantidad terapéuticamente eficaz de pilocarpina, o su sal farmacéuticamente aceptable. También se divulgan métodos para aliviar un efecto secundario del tratamiento de la vejiga hiperactiva en un paciente que sufre de la misma, el método comprendiendo la identificación de un paciente en necesidad del mismo, y la administración al paciente de una cantidad terapéuticamente eficaz de solifenacina de liberación prolongada, o su sal farmacéuticamente aceptable, y una cantidad terapéuticamente eficaz de pilocarpina, o su sal farmacéuticamente aceptable.
MX2013013125A 2011-05-10 2012-05-09 Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva. MX348723B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161484658P 2011-05-10 2011-05-10
PCT/US2012/037006 WO2012154774A1 (en) 2011-05-10 2012-05-09 Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder

Publications (2)

Publication Number Publication Date
MX2013013125A MX2013013125A (es) 2014-02-27
MX348723B true MX348723B (es) 2017-06-27

Family

ID=46124758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013125A MX348723B (es) 2011-05-10 2012-05-09 Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.

Country Status (14)

Country Link
US (3) US8940763B2 (es)
EP (2) EP3167885A1 (es)
JP (2) JP6068447B2 (es)
KR (1) KR20140044816A (es)
CN (1) CN103813792B (es)
AU (1) AU2012253667B2 (es)
BR (1) BR112013028755A2 (es)
CA (1) CA2835277A1 (es)
IL (2) IL229280B (es)
MX (1) MX348723B (es)
RU (1) RU2671575C2 (es)
SG (1) SG194809A1 (es)
WO (1) WO2012154774A1 (es)
ZA (1) ZA201309334B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
BR112013028755A2 (pt) * 2011-05-10 2017-01-31 Theravida Inc combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa
EP3405191B1 (en) 2016-01-20 2025-02-19 TheraVida, Inc. Compositions for use in treating hyperhidrosis
CA3054992A1 (fr) * 2017-03-07 2018-09-13 Olivier Petitjean Prevention des risques associes a un allongement de l'intervalle qt d'origine medicamenteuse a l'aide d'un inhibiteur specifique de la production de ros d'origine mitochondriale

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
EP0310322A3 (en) * 1987-09-30 1990-10-10 Allergan, Inc Use of thromboxane b2 to constrict the pupil and lower intraocular pressure
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
BR9813826A (pt) 1997-12-22 2000-10-10 Euro Celtique Sa Potencial de uso abusivo de administração oral de opióide analgésico
EP2266564B1 (en) 1997-12-22 2013-03-13 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
CN100391438C (zh) 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
MXPA02004574A (es) 1999-11-11 2004-09-10 Pharmacia Ab Formulacion farmaceutica que contiene tolterodina y su uso.
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
EP1635795A1 (en) 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
DE602004030931D1 (es) 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
JP5168711B2 (ja) * 2004-03-25 2013-03-27 アステラス製薬株式会社 ソリフェナシンまたはその塩の固形製剤用組成物
EP1787640A4 (en) 2004-04-30 2012-04-11 Astellas Pharma Inc GRAINED PHARMACEUTICAL COMPOSITION WITH TEMPORARY DELIVERY FOR ORAL ADMINISTRATION AND FAST-DECREASING INTRAORAL TABLET WITH THE COMPOSITION
US20080254115A1 (en) 2004-05-19 2008-10-16 Rubino Orapin P Micropellet Containing Pellets and Method of Preparing Such Pellets
US20070224269A1 (en) 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2006132196A1 (ja) 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
NZ565840A (en) 2005-09-02 2011-07-29 Theravida Inc Therapy for the treatment of disease
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20070077300A1 (en) 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
WO2007046102A2 (en) 2005-10-19 2007-04-26 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
BRPI0809563A2 (pt) 2007-03-29 2014-09-16 Panacea Biotec Ltd Formas de dosagem modificadas de tacrolimus
US7563508B2 (en) 2007-05-30 2009-07-21 Chung Shan Institute Of Science And Technology, Armaments Bureau, M.N.D. Diffusion beads with core-shell structure
EP2173329A1 (en) 2007-07-03 2010-04-14 Synthon B.V. Tolterodine bead
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
PT2205279E (pt) 2007-09-28 2011-07-11 Novartis Ag Associação farmacêutica de aliscireno e valsartan
JP2011502140A (ja) 2007-10-29 2011-01-20 ルピン・リミテッド トルテロジンの制御放出型医薬組成物
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090247628A1 (en) 2008-03-25 2009-10-01 Auspex Pharmaceuticals, Inc. Substituted phenylcyclohexylglycolates
CA2774992A1 (en) * 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
CA2795253A1 (en) 2010-04-01 2011-10-06 Theravida, Inc. Methods of improving quality of sleep
BR112013028755A2 (pt) 2011-05-10 2017-01-31 Theravida Inc combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
US20140037713A1 (en) 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
JP2015533174A (ja) 2012-10-11 2015-11-19 セラヴィダ，インコーポレイテッド ピロカルピンの医薬製剤

Also Published As

Publication number Publication date
JP2014516952A (ja) 2014-07-17
US9132124B2 (en) 2015-09-15
RU2671575C2 (ru) 2018-11-02
US9744157B2 (en) 2017-08-29
IL260345A (en) 2018-08-30
US8940763B2 (en) 2015-01-27
ZA201309334B (en) 2014-08-27
MX2013013125A (es) 2014-02-27
US20120289544A1 (en) 2012-11-15
IL229280B (en) 2018-08-30
EP2706997A1 (en) 2014-03-19
AU2012253667A1 (en) 2013-11-21
EP3167885A1 (en) 2017-05-17
AU2012253667B2 (en) 2017-06-01
SG194809A1 (en) 2013-12-30
IL229280A0 (en) 2014-01-30
WO2012154774A1 (en) 2012-11-15
KR20140044816A (ko) 2014-04-15
RU2013149635A (ru) 2015-06-20
JP6499634B2 (ja) 2019-04-10
CN103813792A (zh) 2014-05-21
US20120289543A1 (en) 2012-11-15
CA2835277A1 (en) 2012-11-15
EP2706997B1 (en) 2019-03-27
JP6068447B2 (ja) 2017-01-25
JP2017078089A (ja) 2017-04-27
US20160213650A1 (en) 2016-07-28
BR112013028755A2 (pt) 2017-01-31
NZ617375A (en) 2016-04-29
CN103813792B (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
WO2012062925A3 (en) Compounds and methods for treating pain
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
TN2013000414A1 (en) 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma
NZ726488A (en) Compositions and methods for transmucosal absorption
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
WO2012170918A3 (en) Methods of treatment for retinal diseases
MX360030B (es) Metodos para tratar el trastorno bipolar.
WO2013085849A3 (en) Sulfate esters of noribogaine
EA201290603A1 (ru) Способ лечения
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
TW201129361A (en) Methods for treating pain
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
WO2014100679A8 (en) Stimulation and enhancement of regeneration of tissues
WO2013177067A3 (en) Herbal composition for treatment of gastrointestinal inflammatory diseases and method to prepare and use thereof
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
WO2014015137A3 (en) Compositions and methods for treating dysproliferative diseases
CA2863829A1 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease

Legal Events

Date Code Title Description
FG Grant or registration